摘要
目的比较单药一线培美曲塞联合或不联合薏苡仁油注射液治疗老年晚期非小细胞肺癌(NSCLC)患者的疗效和不良反应。方法老年晚期NSCLC患者共47例,随机分为治疗组和对照组。治疗组24例,培美曲塞500 mg/m^2,第1天静脉滴注,每3～4周为1周期;同时给予薏苡仁油注射液10g,第1天至第15天静脉滴注;对照组23例,单药培美曲塞化疗。结果治疗组和对照组有效率(RR)分别为41.6%、39.1%,肿瘤控制率(TGCR)分别为70.8%、69.6%,差异无统计学意义(P>0.05)。2组患者对不良反应均可耐受,治疗组耐受性及生存质量均高于对照组,差异有统计学意义(P<0.05)。结论老年晚期NSCLC患者可从单药一线培美曲塞中获益;培美曲塞联合薏苡仁油注射液可减轻化疗相关不良反应,改善患者生存质量。
Objective To observe the efficacy and toxic reaction of pemetrexed or pemetrexed combined with Kanglaite Injection as first-line treatment in elderly patients with advanced non-small cell lung cancer（ NSCLC ）. Methods Forty-seven elderly patients with advanced NSCLC were divided into treatment group and control group randomly. In treatment group,24 cases received pemetrexed at a dose of 500 mg/m2 on day 1 ,repeated every 3-4 weeks as one cycle;in the same time, Kanglaite Injection （10 g） was given intravenously on day 1-15. In control group,23 cases were treated with pemetrexed alone. Results In treatment group and control group,the effective rate was 41.6% and 39. 1% respectively, and the disease control rate was 70. 8 % and 69.6% respectively （P 〉 0. 05 ）. In both groups, the toxicities were tolerable; treatment group showed less toxicity and enjoyed better quality of life （ P 〈 0. 05 ）. Conclusions Elderly patients with NSCLC can benefit from pemetrexed as first-line treatment. Pemetrexed combined with Kanglaite Injection can reduce toxicity of chemotherapy and improve quality of life in elderly patients.
出处
《实用老年医学》
CAS
2012年第1期35-37,共3页
Practical Geriatrics
基金
江苏省卫生厅面上资助项目(H201023)
